South Korean biopharmaceutical giant Celltrion Inc. has introduced its innovative autoimmune disease treatment, Remsima SC, to the Danish market. This subcutaneous formulation of infliximab, previously available as Remsima, marks a significant milestone as it follows recent approvals from both the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA).
Celltrion has been the exclusive supplier for Remsima SC in Denmark since winning a national tender specifically designed for the subcutaneous form of infliximab. This strategic win allows the company to operate without competition in distributing the drug. The distribution is managed through Celltrion’s Danish subsidiary, which has initiated a one-year sales plan this month to capitalize on the market opportunity.
Having entered the Norwegian market earlier in February, the expansion into Denmark underscores Celltrion’s commitment to strengthening its position within Europe. The Danish government’s decision to create a tender for Remsima SC underscores the treatment’s potential and trust in its therapeutic benefits.
In preparation for anticipated growth in demand, Celltrion’s Danish subsidiary is not only increasing its marketing initiatives to boost prescription rates but also planning to expand its local workforce by year’s end. This expansion is aimed at enhancing direct sales capabilities and reinforcing Celltrion’s footprint in the European healthcare sector.
